Sterling Investment Advisors Ltd. Sells 10,500 Shares of Annovis Bio, Inc. (NYSE:ANVS)

Sterling Investment Advisors Ltd. trimmed its position in shares of Annovis Bio, Inc. (NYSE:ANVS) by 30.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,974 shares of the company’s stock after selling 10,500 shares during the period. Sterling Investment Advisors Ltd.’s holdings in Annovis Bio were worth $121,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ANVS. Greenwich Wealth Management LLC grew its position in shares of Annovis Bio by 9.3% in the 3rd quarter. Greenwich Wealth Management LLC now owns 16,475 shares of the company’s stock worth $133,000 after buying an additional 1,400 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Annovis Bio in the 3rd quarter worth about $31,000. State Street Corp boosted its stake in shares of Annovis Bio by 23.7% during the 3rd quarter. State Street Corp now owns 36,035 shares of the company’s stock valued at $290,000 after purchasing an additional 6,900 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Annovis Bio during the third quarter valued at about $76,000. Finally, Atria Wealth Solutions Inc. bought a new position in Annovis Bio in the fourth quarter worth about $65,000. 15.83% of the stock is currently owned by hedge funds and other institutional investors.

Annovis Bio Stock Performance

Shares of NYSE ANVS opened at $1.97 on Tuesday. Annovis Bio, Inc. has a 12-month low of $1.94 and a 12-month high of $20.00. The firm has a 50 day moving average of $4.23 and a 200 day moving average of $6.66.

Analysts Set New Price Targets

Several research firms recently weighed in on ANVS. D. Boral Capital restated a “hold” rating on shares of Annovis Bio in a research report on Monday, February 10th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Annovis Bio in a research note on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.40.

Annovis Bio Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.